SupplyiG0.25MG/TAB(GENDERGINR, 0.5MG/TAB(KINAXR,XANAXR), 1MG/TAB(KINAXR)
UseiGUsed for the management of anxiety disorder or for the short-term relief of symptoms of anxiety. Long term use (more than 4 months) has not been evaluated.
ContraindicationiGHypersensitivity, narrow angle glaucoma.
Adverse effectiGHeadache, insomnia, dizziness, sleepiness, nervousness, tremor, syncope, confusion, depression, nausea, vomiting, diarrhea, constipation, seizure, delirium and withdrawal symptoms have occured in some patients following rapid dosage reduction or abrupt discontinuance of alprazolam.
Usual dosageiGPO 0.5-4mg daily BID or TID
Patient informationiGAvoid alcohol and other CNS depressants; avoid activities needing good psychomotor coordination until CNS effects are known; drug may cause physical or psychological dependence; avoid abrupt discontinuation after prolonged use
BROMAZEPAM
SupplyiG3MG/TAB(LEXOTANR)
UseiGEmotional disturbance, functional disturbance in the cardiovascular and respiratory systems, psychosomatic disorders, emotional reactions to chronic organic disease.
ContraindicationiGMyasthenia gravis.
Adverse effectiGFatigue, drowsiness, muscle weakness.
Usual dosageiG1.5-3mg TID for outpatient therapy. 6-12mg BID or TID for severe cases.
Special precautionsiGElderly & debilitated patients. May impair ability to drive or operate machinery. Drug dependence. Withdrawal precaution.
BUSPIRONE HCL
SupplyiG10MG/TAB(BUSPR)
UseiGBuspirone is an anxiolytic agent chemically unrelated to benzodiazepines. Buspirone is indicated in the treatment of anxiety disorders.
Place in therapy: Studies have shown the drug to be equivalent in efficacy to diazepam on a mg-mg basis, while producing a lower degree of CNS side effects. Compared with diazepam, buspirone produces less sedation, less effect on psychomotor and psychologic function, and a lower propensity for interaction with ethanol and CNS depressants. Buspirone appears to lack the abuse liability of diazepam and other benzodiazepines.
ContraindicationiGHypersensitivity to buspirone or any of its inactive ingredients. Use with caution in patient with MAO inhibitor buspirone does not prevent the symptoms of benzodiazepine withdrawal. If buspirone is intended to replace long-term or chronic benzodiazepine therapy, gradually withdraw the patient from the first drug before initiating buspirone. Also use with caution in patietn with severe renal or hepatic impairment.
Adverse effectiGSide effects is minimal and include dizziness, nausea, headache, nervousness, lightheadedness, and excitement. Buspirone does not appear to be physically addicting.
Usual dosageiGPO 20 to 30 mg/day in divided doses started with initial 7.5 mg PO BID
Special precautionsiGSeizure disorder, renal or hepatic dysfunction.
FLUDIAZEPAM
SupplyiG0.25MG/TAB(ERISPANR)
UseiGFludiazepam is a short acting benzodiazepine with general properties similar to those of diazepam. It is used to treat anxiety disorder.
ContraindicationiGIn patient with narrow angle glaucoma, myasthenia gravis.
Adverse effectiGThe adverse effects similar to those of benzodiazepines: drowsiness (3.8%), dizziness (0.8%), and tiredness (0.8%). Other side effects include: GI symptoms, difficult in urine voiding.
Usual dosageiG1 Tab PO TID
Special precautionsiGResp depression; cardic, hepatic, renal disorder, organic disorder in the brain; infants; elderly; patients with physical weakness.
LORAZEPAM
SupplyiG1MG/TAB(ANXIEDINR, ATIVANR),
UseiGAnxiety, tension, agitation, irritability, insomnia with anxiety, neurosis or transient situational disturbances.
ContraindicationiGHypersensitive to the benzodiazepines, acute narrow angle glaucoma, psychotic reactions, primary depression disorders.
Adverse effectiGSedation, dizziness, weakness, unsteadiness, confusion, headache, sleep disturbance, slight hypotension.
Usual dosageiGUsual dose: 2-6mg/day, up to 10mg/day. Anxiety: 2-3mg/day BID or TID. Insomnia: 2-4mg HS. Elderly patients: 1-2mg/day TID.
Patient informationiGAdvise patient of potential for physical and psychological dependence with chronic use; advise patient of possible retrograde amnesia after I. V. or I.M. use; will cause drowsiness, impairment of judgment or coordination
NORDAZEPAM
SupplyiG5MG/S.C.TAB(CALMDAYR)
UseiGAnxiety &tension linked to functional & psychosomatic disturbances.
ContraindicationiGGlaucoma, myasthenia gravis, pregnancy, lactation.
Adverse effectiGAtaxia, drowsy walk, reduced resp capacity esp in newborn.
Usual dosageiG2 tab in the evening.
Special precautionsiGMay impair ability to drive or operate machinery.
OXAZEPAM
SupplyiG15M/TAB(ALEPAMR)
UseiGAnxiety, tension, irritability, agitation, psychoneurosis.
ContraindicationiGPsychoses; myasthenia gravis, acute narrow angle glaucoma, shock, coma or alcohol intoxication
Adverse effectiGTransient mild drowsiness. Idiosyncratic, allergic or hypersensitivity reactions; rarely leucopenia &hepatic dysfunction.
Usual dosageiGAdult Organic illness or emotional strain 15 mg tid. Severe anxiety &exaggerated stress reactions 15-30 mg 3-4 times daily. Geriatric patients suffering from anxiety 7.5-15 mg 2-3 times daily. Child >6yr0.5 mg/kg daily
BROTIZOLAM
SupplyiG0.25MG/TAB(LENDORMINR)
UseiGInsomnia
ContraindicationiGMyasthenia gravis
Adverse effectiGFatigue &reduced ability to concentrate after waking in patients sensitive to diazepines & following high doses.GI disorder; headache, dizziness; dryness of mouth; drop in BP in hypertensive patients.Tolerance &loss of memory.
Usual dosageiG1 tab at bedtime. Elderly & those decreased clearance 1/2 tab at bed time. In isolated cases, dose may be increased to 2 tab.
DIAZEPAM
SupplyiG2MG,5MG/TAB(VALIUMR)
UseiGTension, anxiety, moderate to severe psycho-neurotic state, acute alcohol withdrawal syndrome, tetanus, convulsive disorders, preoperative medication
ContraindicationiGHypersensitive to diazepam, acute narrow angle glaucoma, psychosis, shock, coma, alcohol intoxication.
Adverse effectiGDrowsiness, depression, confusion, fatigue, ataxia, hypoactivity, bradycardia, cardiovascular collapse.
Usual dosageiGAdults: 2-10mg BID-QID, IM or IV 2-10mg (start).
Child: 0.12-0.8mg/kg/day, IM or IV 1-2mg Q3-4H as needed.
Special precautionsiGCardioresp insufficiency; pregnancy, lactation; myasthenia gravis. May modify psychomotor performances. Dependence; withdrawal precautions.
Patient informationiGAvoid alcohol and other CNS depressants; avoid activities needing good psychomotor coordination until CNS effects are known; drug may cause physicial or psychological dependence; avoid abrupt discontinuation after prolonged use
FLUNITRAZEPAM
SupplyiG2MG/TAB(FLUZEPAMR, MODIPANOLR)
UseiGPreanesthetic medication, induction and maintenance of anesthesia, sleep disturbance.
ContraindicationiGMyasthenia gravis.
Adverse effectiGDrowsiness, hypotension, respiratory difficulty.
Usual dosageiGAdults: Premedication: IM or PO 1-2mg. Induction of anesthesia: slowly IV 1-2mg.
Child: Anesthesia induction: IV 0.03-0.04mg/kg,over 20-30 seconds
Special precautionsiGMay affect psychomotor performances; pregnancy, lactation.
LORMETAZEPAM
SupplyiG1MG/TAB(LORAMETR)
UseiGInsomnia.
ContraindicationiGPregnacy, lactation.
Usual dosageiG1-2 mg 30 mins before bedtime. Elderly 0.5 mg 30 mins before bedtime
SupplyiG0.25MG/TAB(HALCIONR)
UseiGTransient & short-term insomnia, short-term adjunctive treatment in long-term insomnia.
Adverse effectiGDrowsiness, dizziness, lightheadedness, impaired coordination. Occasionally, anterograde amnesia, confusion, agitation.
Usual dosageiGadult 0.25 mg before retiring. Elderly & debilited patient 0.125-0.25 mg(therapy initiated at 0.125 mg) before retiring.
ZOLPIDEM
SupplyiG10MG/F.C.TAB(STILNOXR)
UseiGZolpidem is an imidazopyridine sedative-hypnotic that is structurally unrelated to the barbiturates and benzodiazepines. Zolpidem has been found to be effective for the short-term treatment of insomnia. Other applications have been investigated (eg, preoperative sedation), but further study is needed.
Place in therapy: A significant therapeutic advantage over the benzodiazepines due to its low incidence of adverse effects such as daytime sedation, amnesia, tolerance, dependence, and rebound insomnia upon withdrawal after therapeutic doses. Patients whose insomnia does not resolve after 7 to 10 days should be evaluated for other causes of sleep disturbance. Zolpidem has no anxiolytic properties, thus overuse is possible when used in anxious patients for sleep induction.
ContraindicationiGUse with caution in elderly or debilitated patients, patient with respiratory impairment, patient with hepatic impairment.
Adverse effectiGAdverse effects have been infrequent; anxiety, dizziness, drowsiness, fatigue, headache, irritability, diplopia, and muscle tremors have been reported
Usual dosageiGAdults: 10-20 mg PO QN immediate before sleep; Elderly patients and patients with hepatic impairment should be given an initial dose of 5 mg.
Special precautionsiGResp insufficiency, myasthenia gravis, hepatic & renal insufficiency.
ZOPICLONE
SupplyiG7.5MG/TAB(IMOVANER), 7.5MG/F.C.TAB(GENCLONER)
UseiGZopiclone is a short-acting non-benzodiazepine hypnotic agent. It is effective in the treatment of insomnina.
Place in therapy: In comparison with rapid eliminated benzodiazepines, it offers little or no advantage with regard to residual effects. Rebound insomnia has been reported.
ContraindicationiGHypersensitivity to Zopiclone; caution in patient with severe liver disease and elderly with moderate-to-severe liver disease. The drug should not be prescribed for longer than 28 days.
Adverse effectiGCommon adverse effects of zopiclone are dryness of the mouth and bitter taste, redisual sedation/psychomotor impairment, and rebound insomnia. Physical dependence, psychiatric reaction, including hallucinations, have been reported.
Usual dosageiG7.5 mg PO QN, prolong use should be avoided; dose adjustment are not required in renal insufficiency or in the elderly.
Special precautionsiGPregnancy & lactation. Child <15 yr.
Antipsychotics
CHLORPROMAZINE HCL
SupplyiG50MG/TAB(WINTERMINR)
UseiGSchizophrenia, acute psychoses and to control the manifestations of acute mania; moderate to severe agitation, hyperactivity or aggressiveness in disturbed children, pre-operative medication.
ContraindicationiGPatient with comatose states, bone marrow depression, hypersensitivity to phenothiazines, jaundice, hepatic damage.
Adverse effectiGCNS depression, somnolene, hypotension, extrapyramidal symptoms, agitation, restlessness, convulsion, fever, dry mouth.
Usual dosageiGAdults: PO 10mg TID-QID, or 25mg BID or TID. For promot control of severe symptoms, 25mg IM, repeated 1 hour later, if needed followed by 25-50mg orally TID. Child: PO 0.5mg/kg Q4-6H as needed; IM 0.5mg/kg Q6-8H as needed; maximum dose: 1 g/day
Patient informationiGDo not stop taking unless informed by your physician; do not take antacid within 1 hour of taking drug; avoid alcohol; avoid excess sun exposure (use sun block); may cause drowsiness, rise slowly from recumbent position; use of supportive stockings may help prevent orthostatic hypotension
CLOPENTHIXOL
SupplyiG10MG/TAB(CLOPIXOLR), 200mg/ml/AMP(CLOPIXOL-DEPOTR, 50MG/ML/AMP(CLOPIXOL-ACUPHASER)
UseiGAcute &chronic schizophrenia, psychoses, mania. Mental retardation associated psychomotor, excitation, agitation, violence &other behavioural disturbances.
ContraindicationiGAcute alcohol, barbiturate &opiate intoxication. Pregnancy.
Adverse effectiGExtrapyramidal syndrome; drowsiness, dry mouth, urinary retention, disturbed accommodation, tachycardia, postural hypotension, dizziness. Tardive dyskinesia.
Usual dosageiGChronic schizophrenia & other chronic psychoses 20-40 mg/day. Agitation & confusion in senile patients 2-6 mg/day, may be increase to 10-20 mg/day. Acute schizophrenia, psychoses, agitation, mania Amp 5-20 mg IM up to qid. Tab 10-50 mg/day.
Special precautionsiGHepatic or renal impairment, CV insufficiency, convulsive disorders; may impair ability to drive or operate machinery.
CLOZAPINE
SupplyiG25MG/TAB(CLOPINER,MEZAPINR), 100MG/TAB(CLOZARILR, MEZAPINR)
UseiGClozapine is an atypical antipsychotic agent and a tricyclic dibenzodiazepine derivative.
Place in therapy: The drug has demonstrated efficacy in the therapy of treatment-resistant schizophrenic patients. Because of the higher risk of agranulocytosis, clozapine should be reserved for those treatment-resistant patients who have not responded to adequate trials of other antipsychotic agents.
ContraindicationiGmyeloproliferative disorders, uncontrolled epilepsy, central nervous system depression, comatose state, and a history of clozapine-induced agranulocytosis
Adverse effectiGCommon adverse effects include sedation, dry mouth, nausea, constipation, and sialorrhea. Agranulocytosis is a serious adverse effect of clozapine; white blood cell counts should be monitored weekly for 6 months and every other week thereafter.
Usual dosageiGAdults: 300-600 mg/day; 50-900 mg/day have also been effective; Withdrawal schedule: Gradually reduce the dose over a 1-2 week period.
Child: Safety and effectiveness for use in child has not been established. But for 12-17 y/o as an initial dose of 12.5 -25 mg/day and increased every 4 days by one or two times the starting dose has been reported.
FLUPENTHIXOL
SupplyiG1MG/TAB(FLUANXOLR), 3MG/TAB(FLUANXOL DRAGESSR) 20MG/1ML/AMP(FLUANXOL DEPOR)
UseiGAnxiety, behavior disorders, schizophrenia.
ContraindicationiGComatose patients, particularly those under the influence of alcohol, barbiturate, narcotics or other CNS depression, and in patients with bone marrow depression.
Adverse effectiGExtrapyramidal symptom, restlessness, insomnia, depressive reaction, urinary incontinence, weight gain.
Usual dosageiGAdults: PO 0.5-2mg/day for depression, 16-224mg/day for acute pschosis; IM 10mg/month to 100mg/week.
Child: PO 0.4-2mg/day for 6 months has been used in psychotic/aggressive children
Special precautionsiGHepatic disease, CV or resp disorders, pheochromocytoma, epilepsy, pregnancy, lactation.
HALOPERIDOL
SupplyiG0.5MG/TAB(HALDOLR), 2MG/TAB(ANINR)
UseiGAntidyskinetic (in Gilles de la Tourette's disease), antipsychotic. Depot injection is for the maintenance treatment of psychosis.
ContraindicationiGPatient with severe toxic CNS depression or comatose states or parkinson's disease or hypersensitivity to haloperidol. Neurologic disorders accompained with pyramidal or extrapyramidal symptoms.
Adverse effectiGExtrapyramidal reaction, tachycardia, hypotension, leukopenia, maculopapular and acne form skin reactions, anorexia, constipation.
Usual dosageiGAdults: PO 0.5-2mg BID or TID; for severe symptoms 3-5mg BID or TID, up to a maximum of 100mg/day; for prompt control of moderate to severe symptoms, IM 2-5mg Q1-8H. For Depot injection: IM 50-100mg and 150-200mg every 4 weeks is sufficient for mild and moderate conditions, higher dose 250-300mg for severe case is required.
Special precautionsiGChildren. Hyperthyroidism, hepatic dysfunction, CV disorders.
RISPERIDONE
SupplyiG2MG,3MG/CAP(RISPERDALR)
UseiGRisperidone is indicated for the management of the manifestations of psychotic disorders.
Place in therapy: In contrast to conventional neuroleptics, risperidone act mainly as dopamine antagonists, and blocks both 5-HT2 and dopamine D2 receptors. It may be less likely to cause extrapyramidal symptoms and tardive dyskinesias than other antipsychotics.
ContraindicationiGHypersensitivity to risperidone hyperpro-lactinemia, children and adolescents
Adverse effectiGSedation is the most prominent adverse effect; other infrequent effects include headache, dry mouth, constipation, blurred vision, and urinary retention. Palpitations, nervousness, and lumbalgia have also been reported.
Usual dosageiGPsychotic disorders: 4-8 mg/day PO beginning with 1 mg BID initially, with increases in increments of 1 mg BID on the second and third day, as tolerated, to a target dose of 3 mg BID by the third day.
SULPIRIDE
SupplyiG200MG/TAB(UISPANR), 200MG/F.C.TAB(DOGMATYLR)
UseiGSulpiride is a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. It is used for tranquillization, antipsychotic, mood elevating, antiemetic, anti-gastrin secretion.
ContraindicationiGHypersensitivity, phaeochromocytoma, hypertension
Adverse effectiGPredominant adverse effects have been extra-pyramidal reactions and sedation. Tardive dyskinesia has been reported; similar to other neuroleptics, sulpiride has been associated with neuroleptic malignant syndrome and cholestatic jaundice. Other adverse effects are sleep disturbances, over-stimulation, and agitation
Usual dosageiG1. Schizophrenia: PO, initial: 200-400mg BID, increased if necessary, up to maximum 1.2g/day.
2. Child: 3-5mg/kg
3.Gastric and duodenal ulcers: 150-300mg daily
THIORIDAZINE HCL
SupplyiG25MG/F.C.TAB(MELLERILR)
UseiGSchizophrenia and acute psychosis.
ContraindicationiGPatient with extreme hypotensive or hypertensive heart disease or severe CNS depression or comatose states.
Adverse effectiGDrowsiness, pseudo-parkinsonism, extra-pyramidal symptoms, dry mouth, blurred vision, constipation, dermatitis, urticaria.
Usual dosageiGAdults: 50-100mg TID to start, followed by a gradual increase up to 800mg/day for control, then 200-800mg/day in 2-4 divided doses. Child (2-12 yr): 10mg BID or TID to start, followed by large doses until optimum responses is obtained or maximum dosage 3mg/kg/day is reached.
Patient informationiGOral concentrate must be diluted in 2-4 oz of liquid (water, fruit jiuice, carbonated drinks, milk, or pudding); do not take antacide within 1 hour of taking drug; avoid excess sun exposure; may cause drowsiness, restlessness, avoid alcohol and other CNS depressants; do not alter dosage or discontinu without consulting physician; yearly eye exams are necessary; might discolor urine(pink or reddish brown)
Drugs used for affective disorders
AMITRIPTYLINE HCL
SupplyiG25MG/CAP(SAROTEN RETARDR)
UseiGDepression, especially endogenous depression.
ContraindicationiGHypersensitivity, wait at least 14 days after discontinuing MAO inhibitors before initiating amitriptyline therapy.
Adverse effectiGHypotension, tachycardia, palpitations, arrhythmia, confusion, dry mouth, blurred vision, urinary retention, bone marrow depression, constipation.
Usual dosageiGQID to start, replace with oral therapy as soon as possible. Adults: PO 75mg/day divided to start, followed by increase in late-afternoon or bedtime dose, up to 150mg/day.
Special precautionsiGConvulsive disorders. Urinary retention. Advanced hepatic disease. Suicidal tendency. Attacks of intermittent blurring of vision, rainbow vision & ocular pain. Elder, child <5 yr
CITALOPRAM
SupplyiG20MG/TAB(CIPRAMR)
UseiGDepression.. Panic disorders.
Adverse effectiGDry mouth, nausea, increased sweating & tremor, somnolence
Usual dosageiGInitially 20 mg once a day. Max: 60 mg daily. Elderly > 65 yr 20mg daily, may be increased to a max of 40 mg daily.
Special precautionsiGPregnancy, lactation, mania.
FLUOXETINE
SupplyiG20MG/CAP(SINZACR, U-ZETR, PROZACR)
UseiGIt is an antidepressant that is a specific inhibitor of serotonin reuptake. It is as effective in the treatment of depression as amitriptyline, imipramine and doxepin but with lower degree of toxicity.
ContraindicationiGUse with cautison in patient with renal or hepatic disease. The washout period between use of fluoxetine and MAOI is 5 weeks.
Adverse effectiGNausea, hypotension, headache, anxiety, nervousness, insomnia, dry mouth, anorexia and visual disturbances, weight loss.
Usual dosageiG20 to 80mg/day, range from 5-60mg/day has been suggested.
Special precautionsiGControlled epilepsy, renal & hepatic impairment, insomnia if treatment in the evening.
IMIPRAMINE
SupplyiG10MG/TAB(TOFRANILR), 25MG/S.C.TAB(IMINER)
UseiGDepression, especially endogenous depression and childhood enuresis.
ContraindicationiGHypersensitivity to imipramine or other benzodiazepines; wait at least 14 days after discontinuing MAO inhibitors before initiating imipramine therapy, myocardial infarction during acute recovery phase.
Adverse effectiGDrowsiness, tachycardia, congestive heart failure, mydriasis, convulsion, hypotension, confusion, dry mouth, bone marrow depression, nausea, vomiting
Usual dosageiGAdults: PO 75mg/day to start, followed by up to 200mg/day if needed, usual maintenance dose: 50-150mg/day.
Special precautionsiGConcomitant administration with MAOIs. CV disturbances, AV block (grades I-III), arrhythmias, hypotersion. Narrow-angel glaucoma, disturbances of micturition, lowered convulsion threshold. Road users. Pregnancy, lactation.
LITHIUM CARBONATE
SupplyiG300MG/TAB(LIDINR), 300MG/CAP(LITHONATER), 400MG/F.C.TAB(CAMCOLIT-400R)
UseiGManic episodes of manic depressive illness.
ContraindicationiGPatient with renal impairment or cardiac disease.
Adverse effectiGDiarrhea, vomiting, drowsiness, arrhythmia, muscular weakness, hypotension, blurred vision, dry mouth.
Usual dosageiGAdults: For acute episode, 600mg TID; for maintenance 300mg TID or QID; maximum dose: 2.4 g/day
Special precautionsiGElderly. Diuretic therapy. Pregnancy. Pre-treatment & periodic routine clinical monitoring is essential.
MOCLOBEMIDE
SupplyiG150MG/F.C.TAB(AURORIXR, EUTAER)
UseiGMoclobemide is a selective and reversible inhibitor of monoamine oxidase-A. Moclobemide is effective in the treatment of endogenous and non-endogenous depression.
Place in therapy: In most comparative studies, moclobemide has been better tolerated than tricyclic antidepressants, particularly with regard to a lower frequency of anticholinergic effects. No interaction has been reported between moclobemide and tricyclic antidepressants.
ContraindicationiGPrevious hypersensitivity to moclobemide; in patients in an acute confusional state. The concomitant use of moclobemide with selective serotonin reuptake inhibitors, conventional MAO inhibitors, or tricyclic antidepressants is contraindicated. Moclobemide should not be used in combination with meperidine.
Adverse effectiGThe most frequent adverse effect of moclobemide is dry mouth (28%); other adverse effects include dizziness, headache, tremor, insomnia, constipation, nausea, blurred vision, hypotension, and tachycardia. Hypertensive responses as a result of tyramine interaction have been relatively rare.
Usual dosageiGAdults: 300 to 600 mg daily, in 3 divided doses; in patient with liver cirrhosis, a one-half to one-third dose reduction is suggested.
Special precautionsiGAcute confusional states. Pregnancy, lactation; ped age group. Depressive patients excitation or agitation as the predominant clinical feature should be treated in combination with a sedative.
SERTRALINE
SupplyiG50MG/F.C.TAB(ZOLOFTR)
UseiGSertraline is an antidepressant with selective inhibitory effects on presynaptic serotonin (5-HT) reuptake. It is effective in the treatment of depression, obsessive compulsive disorder (OCD), and panic disorder.
Place in therapy: Sertraline is unique among the antidepressants because it seems to cause less of the sedating, anticholinergic, and cardiovascular adverse effects common to other agents, possibly due to its high specificity for the serotonin receptor.
ContraindicationiGConcurrent use of monoamine oxidase inhibitor (MAOI) drugs. At least 2 weeks are required after ceasing a MAO inhibitor and then begin the drug, and.vis versa.
Adverse effectiGNausea and vomiting may occur, as may diarrhea and dry mouth.
Usual dosageiGInitial doses:50 mg PO QD; maximum doses are 200 mg PO QD
Special precautionsiGHepatic insufficiency; electroconvulsive therapy, unstable epilepsy; may impair ability to drive or operate machinery; pregnancy, lactation; children.
TRAZODONE HCL
SupplyiG50MG/TAB(MESYRELR), 100MG/TAB(TRAZONER)
UseiGTrazodone is used primarily in the treatment of mental depression or depression/anxiety disorder.
Place in therapy: Trazodone may be safely combined with MAOIs for refractory depression. Disadvantages of trazodone include a high incidence of priapism, orthostatic hypotension, and induction or exacerbation of atrial and ventricular arrhythmias. However, compared with the TCAs, trazodone is still considered less cardiotoxic.
ContraindicationiG1) Hypersensitivity to trazodone 2) Carcinoid syndrome 3) Trazodone is not recommended for use during initial recovery phase of myocardial infarction.
Adverse effectiGTrazodone has a low incidence of anticholinergic effects and cardiovascular effects. Adverse effects includes: ventricular arrhythmias, hypotension, heart block, drowsinness, weight gain, blurred vision, dizziness, and priapism.
Usual dosageiG50-600mg daily, usually response range between 100-300mg daily in single or divided dose.
Special precautionsiGPregnancy & lactation. Children <18yr
VENLAFAXINE
SupplyiG37.5MG/TAB(EFEXORR)
UseiGTreatment of depression, including depression associated with anxiety, in both hospitalized patients & outpatients.
ContraindicationiGConcomitant use in patient taking MAOIs. Pregnancy, lactation. Children <18yr.
Adverse effectiGDizziness, dry mouth, insomnia, nervousness, somnolence, anorexia, constipation, nausea, abnormal ejaculation/orgasm, sweating, asthenia.
Usual dosageiGUsually 75mg/day in 2 divided doses. Dose may be increased to 150mg/day in 2 divided doses.
Now: 
